Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,468.00
Bid: 12,466.00
Ask: 12,470.00
Change: 76.00 (0.61%)
Spread: 4.00 (0.032%)
Open: 12,468.00
High: 12,508.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTED-UPDATE 5-Japan approves more COVID-19 vaccines, expands state of emergency

Fri, 21st May 2021 04:06

(Corrects AstraZeneca comment)

By Chang-Ran Kim

TOKYO, May 21 (Reuters) - Japan expanded a state of
emergency to cover the southern island of Okinawa on Friday, as
authorities approved two more coronavirus vaccines to speed a
lagging inoculation campaign.

The newly approved vaccines, from Moderna Inc and
AstraZeneca PLC, will join the one co-developed by
Pfizer Inc and BioNTech SE in a vaccination
drive that began in mid-February.

Earlier media said the government would hold off on the use
of AstraZeneca's vaccine because of concerns over blood clots
and bleeding in some. The company said it was aware of the
government's decision that its vaccine would not be immediately
used.

"We'll do our utmost in working to ensure that all elderly
people who seek vaccinations can get their two shots by the end
of July," Economy Minister Yasutoshi Nishimura, who is leading
the coronavirus response effort, told reporters.

Japan has vaccinated just 4.1% of its population, according
to Reuters' global tracker https://tmsnrt.rs/3vbj5CE, the
slowest rate among the world's larger, rich countries.

In contrast to some other Group of Seven (G7) nations that
are beginning to end pandemic-busting lockdown measures, much of
Japan remains under emergency curbs amid a fourth wave of
infections.

On Friday, the government added Okinawa to its list of nine
prefectures placed under the strictest emergency measures. They
include Tokyo, where the Olympic Games are due to start in about
two months.

JAPAN INC, PUBLIC FEARS OVER OLYMPICS

Fears that the Olympics would turn into a super-spreader
event have persisted, ensuring opposition by the majority of the
public to holding the Games this year.

A Reuters corporate survey https://jp.reuters.com/article/us-olympics-2020-japan-companies-poll/fretting-about-covid-most-japan-firms-say-olympics-should-be-cancelled-or-postponed-reuters-poll-idUSKCN2D12SZ
published on Friday showed nearly 70% of Japanese firms also
want the Games either cancelled or postponed.

The state of emergency for Okinawa would run for about a
month, from Sunday through June 20, Prime Minister Yoshihide
Suga said, beyond the May 31 end-point of the other nine.

It is the third consecutive week that Japan is expanding the
state of emergency. With about 695,000 infections and 12,000
deaths, Japan is finding its medical system increasingly
strained by a spike in more infectious variants.

With the Olympics starting on July 23, Tokyo is under
particular pressure to cut infections and the strain on the
medical system and emerge from the emergency on schedule this
month.

After a 30-minute meeting with Suga on Friday, Tokyo
Governor Yuriko Koike said she sought vaccine supplies for the
capital, which begins mass vaccinations next week.

The two agreed to work towards a "safe and secure" Olympics
this summer, they later told reporters.
(Reporting by Chang-Ran Kim; Additional reporting by Rocky
Swift, Ritsuko Ando and Ju-Min Park; Editing by Christopher
Cushing and Clarence Fernandez)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.